IGC Pharma (IGC) Other Accumulated Expenses (2011 - 2026)
IGC Pharma (IGC) posted quarterly Other Accumulated Expenses of $101000.0 for Q1 2026, down 89.93% year-over-year from $1.0 million in Q1 2025, and down 49.5% quarter-over-quarter from $200000.0 in Q4 2025.
IGC Pharma (IGC) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Other Accumulated Expenses for 12 consecutive years, with $101000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses fell 89.93% year-over-year to $101000.0; the TTM figure through Mar 2026 stood at $101000.0 (down 89.93% YoY), while the FY2026 annual figure was $101000.0, down 89.93% from the prior year.
- Other Accumulated Expenses slipped to $101000.0 in Q1 2026 per IGC's latest filing, from $200000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.0 million in Q1 2025 and bottomed at $101000.0 in Q1 2026.
- Historically, Other Accumulated Expenses has averaged $376545.5 across 4 years, with a median of $333000.0 in 2025.
- Annual changes were most pronounced in 2025 — Other Accumulated Expenses surged 382.21% — and 2026, when it slumped 89.93%.
- IGC Pharma's Other Accumulated Expenses stood at $210000.0 in 2023, then plunged by 44.29% to $117000.0 in 2024, then surged by 70.94% to $200000.0 in 2025, then slumped by 49.5% to $101000.0 in 2026.
- Business Quant data shows IGC's Other Accumulated Expenses at $101000.0 in Q1 2026, $200000.0 in Q4 2025, and $333000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 101,000.00 |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 333,000.00 |
| Jun 30, 2025 | 401,000.00 |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 117,000.00 |
| Sep 30, 2024 | 794,000.00 |
| Jun 30, 2024 | 417,000.00 |
| Mar 31, 2024 | 208,000.00 |
| Dec 31, 2023 | 210,000.00 |
| Mar 31, 2023 | 358,000.00 |
| Sep 30, 2018 | 659,000.00 |
| Jun 30, 2018 | 426,199.00 |
| Mar 31, 2018 | 494,000.00 |
| Dec 31, 2017 | 474,101.00 |
| Sep 30, 2017 | 409,597.00 |
| Jun 30, 2017 | 407,169.00 |
| Mar 31, 2017 | 873,179.00 |
| Jun 30, 2016 | 424.00 |
| Mar 31, 2016 | 550,877.00 |